Physiological Based Pharmacokinetic Modeling and Simulation (PBPK)

PI-097 - MECHANISTIC MODELING OF SPATIAL HETEROGENEITY OF DRUG PENETRATION AND EXPOSURE IN THE HUMAN CENTRAL NERVOUS SYSTEM AND BRAIN TUMORS

PI-098 - PBPK MODEL REPRODUCIBILITY: LEARNINGS FROM THE DEVELOPMENT OF A PBPK MODEL REPOSITORY FOR GLOBAL HEALTH

PI-101 - PREDICTING BRINZOLAMIDE OCULAR RESPONSE IN HUMANS USING AN OCULAR PBPK-PD MODELING AND SIMULATION

PI-102 - PREDICTION OF A CLAUDIN 18.2 TARGETED ANTIBODY DRUG CONJUGATE (ADC) PHARMACOKINETICS IN CANCER PATIENTS USING PBPK MODELING AND SIMULATION

PI-103 - UTILISING PHYSIOLOGICAL LYMPH FLOWS TO ENHANCE A MINIMAL PHYSIOLOGICALLY BASED PHARMACOKINETIC AND QUANTITATIVE SYSTEMS PHARMACOLOGY MODEL FOR BIODISTRIBUTION OF MRNA ENCAPSULATED IN LIPID NANOPARTICLES WITH LIPID 5 IN RATS

PII-095 - ASSESSMENT OF THE IMPACT OF NON-COMPARABLE IN VITRO ALCOHOL DOSE DUMPING RELEASE ON SYSTEMIC EXPOSURE USING PBPK ABSORPTION MODELING FOR TOPIRAMATE EXTENDED-RELEASE CAPSULES.

PII-096 - DEVELOPMENT OF A PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL TO PREDICT PHARMACOKINETICS AND DRUG-DRUG INTERACTIONS FOR REPOTRECTINIB

PII-097 - MECHANISTIC INSIGHTS INTO CYTOKINE ANTAGONIST-DRUG INTERACTIONS: A PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING APPROACH WITH TOCILIZUMAB AS A CASE STUDY

PII-098 - ON TRANSLATING PHYSIOLOGICALLY BASED PHARMACOKINETICS INTO CLINICAL CARE: REAL-WORLD PREDICTABILITY OF VALPROATE THERAPEUTIC DRUG MONITORING.

PII-099 - PBPK MODELING TO PREDICT THE EFFECT OF GASTRIC PH ON BIOEQUIVALENCE OF PALBOCICLIB TABLETS

PII-100 - PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODELLING FOR PREDICTING DRUG-DRUG INTERACTIONS (DDI) OF SHR2554

PII-104 - UTILIZING A MINIMAL PBPK (MPBPK) MODEL TO PREDICT INTRA-TUMORAL CONCENTRATIONS OF MONOCLONAL ANTIBODIES.

E-003 - A QUANTITATIVE SYSTEMS PHARMACOLOGY QSP) MODEL FRAMEWORK FOR COMBINED CLINICAL EFFICACY AND HEMATOLOGICAL TOXICITY PRECITIONS FOR ANTIBODY DRUG CONJUGATES.

E-004 - DEVELOPMENT OF QSP PLATFORM MODEL FOR PREDICTING CLINICAL EFFICACY AND CRS INCIDENCE OF CD3 BISPECIFICS IN STEAP1 PROSTATE CANCER

LB-017 - ASSESSING THE IMPACT OF AGE ON CANNABINOID DISPOSITION

LB-019 - CAN PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING COMPLEMENT THERAPEUTIC DRUG MONITORING FOR DIGOXIN DOSE OPTIMIZATION IN PATIENTS WITH RENAL IMPAIRMENT?

LB-020 - DEVELOPMENT OF AN R SHINY APPLICATION TO STREAMLINE DRUG-DRUG INTERACTION SIMULATIONS UTILIZING THE SIMCYP-R PACKAGE.

PWI-003 - ADVANCEMENTS IN PEDIATRIC PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODELING OF DRUGS IN LACTATION FOR GUIDING NEONATAL EXPOSURE RISK ASSESSMENT

PWII-002 - DEVELOPMENT OF ADEFOVIR PBPK MODEL TO SUPPORT PROSPECTIVE EVALUATION OF BIOMARKER-INFORMED OAT1 INHIBITION AND EFFECT OF RENAL IMPAIRMENT